Brief: Synlogic Initiates Phase 1 Study Of Synb1353 For Treatment Of Homocystinuria

Synlogic

12/07/2022 12:17

July 12 (Reuters) - Synlogic Inc  SYBX.O :
    * SYNLOGIC INITIATES PHASE 1 STUDY OF SYNB1353 FOR THE
TREATMENT
OF HOMOCYSTINURIA (HCU)
    * SYNLOGIC INC - EXPECTS TO SHARE RESULTS FROM PHASE 1 STUDY
OF
SYNB1353 IN HEALTHY VOLUNTEERS BY END OF 2022

Source text for Eikon:  ID:nGNXc4JxbM 
Further company coverage:  SYBX.O 

 ((Reuters.Briefs@thomsonreuters.com;))